Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
7(100.0%)
7Total
Phase 1(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT01890213Phase 1Completed

Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer

Role: collaborator

NCT00706732Phase 1Completed

A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza

Role: lead

NCT00529984Phase 1Completed

A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies

Role: lead

NCT00097838Phase 1Completed

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

Role: lead

NCT00063778Phase 1Completed

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

Role: lead

NCT00439803Phase 1Completed

A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)

Role: lead

NCT00440362Phase 1Completed

A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza

Role: lead

All 7 trials loaded